0874.HK Baiyunshan Pharma Earnings: Revenue Hits $26.45B

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) released earnings on April 27, 2026, posting $26.45 billion in revenue and $1.25 earnings per share. The pharmaceutical giant operates across Chinese patent medicines, Western medicines, and healthcare services. With a $41.05 billion market cap and 281,380 employees, Baiyunshan remains a major player in China’s healthcare sector. The company trades at HK$16.78 with a 7.83 price-to-earnings ratio. Meyka AI rates 0874.HK with a grade of B, suggesting a hold position for investors monitoring this healthcare leader.

Earnings Results and Financial Performance

Baiyunshan delivered solid financial results in its latest earnings report. The company generated $26.45 billion in total revenue, demonstrating its scale across multiple business segments. Earnings per share reached $1.25, reflecting the company’s profitability despite challenging market conditions.

Revenue Strength Across Segments

The pharmaceutical company’s revenue base spans four key divisions: Great Southern TCM, Great Commerce, Great Health, and Others. This diversified portfolio includes Chinese patent medicines, Western pharmaceuticals, chemical raw materials, and healthcare products. The company operates 154 retail pharmacy outlets across China, including branded chains like Cai Zhi Lin and Jian Min pharmacies. This retail network provides direct consumer access and strengthens distribution capabilities.

Profitability Metrics

With $1.25 in earnings per share, Baiyunshan demonstrates consistent profitability. The company’s net profit margin stands at 3.86%, indicating moderate efficiency in converting revenue to bottom-line earnings. Operating margins of 4.29% show reasonable cost control across manufacturing and distribution operations. These metrics reflect the competitive nature of China’s pharmaceutical industry.

Stock Performance and Valuation

Baiyunshan’s stock showed minimal movement on earnings day, reflecting market sentiment toward the results. The stock trades at HK$16.78, down just 0.12% from the previous close. This muted reaction suggests investors viewed the earnings as in-line with expectations.

Valuation Metrics

The company trades at a 7.83 price-to-earnings ratio, well below the healthcare sector average. This valuation appears attractive for value-oriented investors seeking exposure to China’s pharmaceutical market. The price-to-sales ratio of 0.46 indicates the market values Baiyunshan at less than half its annual revenue. The price-to-book ratio of 0.62 suggests the stock trades at a discount to tangible asset value.

Technical Position

Technical indicators show weakness in the near term. The RSI of 32.27 indicates oversold conditions, while the MACD remains negative at -0.34. The ADX of 33.98 signals a strong downtrend in place. However, the dividend yield of 5.30% provides income support for long-term holders.

Business Segments and Operations

Baiyunshan operates a complex, integrated healthcare business serving millions of Chinese consumers. The company’s diversified model reduces dependence on any single product or market segment.

Pharmaceutical Manufacturing and Distribution

The Great Commerce segment handles wholesale and retail distribution of Western and Chinese medicines. This division includes import-export operations and medical device sales. The company maintains strong relationships with hospitals, clinics, and retail pharmacies across China. Manufacturing capabilities span tablets, capsules, injections, and traditional remedies.

Healthcare and Consumer Products

The Great Health segment produces beverages, food products, healthcare supplements, and dairy items. This division also manages elderly care services and health preservation programs. The company invests in medical care facilities and health management operations. These services address China’s aging population and growing wellness demand.

Retail Pharmacy Network

Baiyunshan operates 154 retail pharmacy outlets providing direct consumer access. The Cai Zhi Lin, Jian Min, and GPC Prescription Pharmacy brands serve different market segments. This retail presence strengthens brand recognition and customer loyalty. The network generates recurring revenue and valuable consumer data.

Financial Health and Investor Considerations

Baiyunshan maintains solid financial fundamentals supporting long-term operations. The company’s balance sheet shows manageable leverage and adequate liquidity for growth investments.

Balance Sheet Strength

The company holds $14.65 in cash per share, providing financial flexibility. The current ratio of 1.57 indicates strong short-term liquidity to meet obligations. Debt-to-equity stands at 0.55, showing moderate leverage levels. The interest coverage ratio of 8.30 demonstrates comfortable ability to service debt obligations.

Cash Flow and Returns

Operating cash flow remains positive, though free cash flow turned negative at -$0.70 per share. This reflects capital investments in retail expansion and facility upgrades. The company maintains a 5.30% dividend yield, returning cash to shareholders. Return on equity of 7.90% shows reasonable profitability relative to shareholder capital invested.

Meyka AI Assessment

Meyka AI rates 0874.HK with a grade of B, suggesting a hold position. The rating reflects balanced fundamentals with both strengths and concerns. Strong valuation metrics and dividend yield support the stock, while negative cash flow trends warrant monitoring.

Final Thoughts

Guangzhou Baiyunshan Pharmaceutical delivered $26.45 billion in revenue and $1.25 earnings per share, demonstrating the company’s scale and profitability in China’s competitive pharmaceutical market. The stock’s muted reaction reflects investor acceptance of results. Trading at a 7.83 P/E ratio and offering a 5.30% dividend yield, Baiyunshan appeals to value investors seeking healthcare exposure. However, technical weakness and negative free cash flow trends require attention. Meyka AI’s B grade suggests holding the position while monitoring quarterly progress on cash generation and retail expansion initiatives.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.